post operative pain management after knee arthroplasty

Study of Transdermal Buprenorphine patch versus oral Etoricoxib for post operative pain management after total knee arthroplasty: A Randomised comparative, an open label study - Nil

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058580

Enrollment

Registered

2023-10-12

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S809- Unspecified superficial injury ofknee and lower leg

Interventions

Intervention1: First group A group will receive oral Etoricoxib 90 mg 1 hour before surgery with a sip of water and repeated after 12 hrs for 1 week: 12 hrs for 1 week Control Intervention1: Ringer la

Eligibility

Inclusion criteria

Inclusion criteria: Patients with either sex, ASA 1,2 and 3 ,age 18 to 70 years having diagnosis of knee osteoarthritis undergoing elective unilateral total knee arthroplasty Patients giving written informed consent will be taken

Exclusion criteria

Exclusion criteria: Patient not giving consent Pregnant women Lactating women Contraindications for spinal anaesthesia Patient with medical history of cardiopulmonary diseases, cerebrovascular diseases, liver and renal dysfunctions Opioid-dependent and opioid sensitive patients, Patients with psychiatric illness and on medication Haemodynamically unstable and morbidly obese patients Case of spinal anaesthesia getting converted into general anaeshesia due to intraoperative complications

Design outcomes

Primary

Measure	Time frame
To establish superiority of transdermal buprenorphine patch over oral etoricoxib for postoperative pain management after total knee arthroplasty in terms of pain score among the groups A and B at rest and on movements in post operative period by using VAS score upto 7 daysTimepoint: To establish superiority of transdermal buprenorphine patch over oral etoricoxib for postoperative pain management after total knee arthroplasty in terms of pain score among the groups A and B at rest and on movements in post operative period by using VAS score upto 7 days	—

Measure

Time frame

To establish superiority of transdermal buprenorphine patch over oral etoricoxib for postoperative pain management after total knee arthroplasty in terms of pain score among the groups A and B at rest and on movements in post operative period by using VAS score upto 7 daysTimepoint: To establish superiority of transdermal buprenorphine patch over oral etoricoxib for postoperative pain management after total knee arthroplasty in terms of pain score among the groups A and B at rest and on movements in post operative period by using VAS score upto 7 days

—

Secondary

Measure	Time frame
To compare total rescue analgesic requirement upto 7 days Incidence of nausea and vomiting upto 7 days Length of hospital stay Timepoint: 12 hrs to 7 days	—

Countries

India

Contacts

Public ContactDr Shefali Gautam

King Georges Medical University Lucknow

drshefaligautam@gmail.com9559468440

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026